Aside from NF1 and NF2 genes, CHEK2 and TP53 variants, heralding Li–Fraumeni syndrome, are actionable in terms of tailoring specific surveillance plans for these patients who harbor a high risk for cancer development throughout life. This evidence concerns the gene CHEK2 and cancer.